|
**Overview**: FISH CLL Panel**Introduction**: The FISH CLL Panel is a diagnostic tool designed to screen for chromosomal abnormalities in chronic lymphocytic leukemia using whole blood or bone marrow samples. In India, CLL is the most common adult leukemia in Western populations but increasing in urban areas (incidence ~1-2 per 100,000), with FISH detecting high-risk abnormalities (del(17p), del(11q), trisomy 12, del(13q)) in ~50-80 percent of cases, guiding prognosis and targeted therapy (e.g., venetoclax/ibrutinib for del(17p)). High morbidity from under-testing in rural/low-SES patients, limited FISH labs, delayed risk-adapted treatment leading to poor survival. Per hematology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs fluorescence in situ hybridization (FISH) for CLL-specific rearrangements over 1-2 days with high sensitivity/specificity, valuable for prognostic stratification at diagnosis and relapse. This diagnostic falls under leukemia screening and targets CLL patients (especially Rai/Binet advanced stage), addressing accurate detection to guide BTK inhibitors or clinical trials. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise molecular prognostication and improving outcomes. Its blood/bone marrow-based approach ensures reliable abnormality detection in India's growing hematology-oncology centers.**Other Names**: FISH CLL Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics/oncology, compliant with 2025 standards.**Historical Milestone**: CLL FISH prognostic panel; in India, expanding in hematology labs.**Purpose**: The test detects 2 parameters including CLL-specific rearrangements to guide genetic assessment, identify high-risk features, inform therapy/prognosis.**Test Parameters**: 1. CLL-Specific Rearrangements, 2. Chromosomal Abnormalities.**Pretest Condition**: No fasting required; patients should have confirmed CLL diagnosis.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for FISH).**Medical History**: Patients should provide details on CLL stage, symptoms, prior therapy, lymphocytosis.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected high-risk abnormalities including poor response, benefits of profiling, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low lymphocyte count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High-risk abnormalities (del(17p)/del(11q)) indicate poor prognosis, necessitating specialist input. Favorable (del(13q)) may require follow-up.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: IGHV mutation, TP53 sequencing for confirmation.**Test Limitations**: Detects specific loci only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, CLL Studies India 2023. |
